Forex Trading

Allspring Global Investments Holdings LLC Sells 633 Shares of Zentalis Pharmaceuticals, Inc NASDAQ:ZNTL
performance hematological malignancies

The firm’s fifty day simple moving average is $19.64 and its 200 day simple moving average is $20.93. The firm has a market capitalization of $1.06 billion, a P/E ratio of -3.95 and a beta of 1.87. Options trading entails significant risk and is not appropriate for all investors. Option investors can rapidly lose the value of their investment in a short period of time and incur permanent loss by expiration date. You need to complete an options trading application and get approval on eligible accounts. Please read the Characteristics and Risks of Standardized Options before trading options.

That means your assets are protected up to $500,000 in value, including $250,000 in any cash awaiting reinvestment. Zentalis Pharmaceuticals stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period. Below are the latest news stories about ZENTALIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ZNTL as an investment opportunity. We have 9 different ratings for every stock to help you appreciate its future potential.

Inflation & Prices

While the effectiveness of this highly sought-after metric is questionable, the posi… Wells Fargo, on the other hand, stated in their research note that they expect to see ZNTL reach a price target of $67. The rating they have provided for ZNTL stocks is “Overweight” according to the report published on April 06th, 2022. The stock of Zentalis Pharmaceuticals Inc. has seen a -7.75% decrease in the past week, with a -9.63% drop in the past month, and a -8.53% decrease in the past quarter.

Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds. The price-earnings ratio is a company’s share price to the company’s Earnings per Share. The ratio is used for evaluating companies and to find out whether they are overvalued or undervalued. The price-to-book ratio is a company’s current market price to its Book Value. Traditionally, any value under 1.0 is considered a good P/B value, indicating a potentially undervalued stock. We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer.

Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. SVB Securities analyst Andrew Berens maintained a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report) today and set a price target of $27.00. The company’s shares closed yesterday at $18.39.According to TipRank… Zentalis Pharmaceuticals has a 1 year low of $15.55 and a 1 year high of $52.85.

It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY. Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. 8 Wall Street research analysts have issued 12 month target prices for Zentalis Pharmaceuticals’ shares.

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

Wall Street Analysts Are Bullish on Top Healthcare Picks

That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. Zentalis Pharmaceuticals set terms of its initial public offering, in which the biopharmaceutical company developing cancer treatments is expected to raise up to $137.7 million. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.98.

  • Advisory accounts and services are provided by Webull Advisors LLC (also known as “Webull Advisors”).
  • ZN-d5 is a selective, oral small molecule inhibitor of B-cell lymphoma 2 (BCL-2), which is currently being evaluated in patients with hematologic malignancies.
  • It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Fusion Mediawould like to remind you that the data contained in this website is not necessarily real-time nor accurate. In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument. The company’s average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings. During the last 5 trading sessions, ZNTL fell by -7.70%, which changed the moving average for the period of 200-days by -35.87% in comparison to the 20-day moving average, which settled at $18.27.

Its specialists are interested in stocks that have been undervalued by different reasons. They are trying to find them, count their potential and bring them to their clients. Bunker Kevin D., the Chief Scientific Officer of Zentalis Pharmaceuticals Inc., sale 6,500 shares at $19.98 during a trade that took place back on Feb 14, which means that Bunker Kevin D.

Key Data

Information is provided ‘as-is’ and solely for informational purposes, not for purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. One share of ZNTL stock can currently be purchased for approximately $17.41.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average … – MarketBeat

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average ….

Posted: Tue, 04 Apr 2023 06:14:28 GMT [source]

Separately, ZNTL on Monday priced its underwritten offering of 10.3M shares at an offering price of $19.38/share for total gross proceeds of ~$200.2M. No content on the Webull Financial LLC website shall be considered as a recommendation or solicitation for the purchase or sale of securities, options, or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.

According to 17 analysts, the average rating for ZNTL stock is “Buy.” The 12-month stock price forecast is $52.22, which is an increase of 199.94% from the latest price. The Fund Sentiment Score finds the stocks that are being most bought by funds. It is the result of a sophisticated, multi-factor quantitative model that identifies companies with the highest levels of institutional accumulation. The scoring model uses a combination of the total increase in disclosed owners, the changes in portfolio allocations in those owners and other metrics. The number ranges from 0 to 100, with higher numbers indicating a higher level of accumulation to its peers, and 50 being the average. The chart below shows how a company’s ratings by analysts have changed over time.

Zentalis Pharmaceuticals Price prediction day by day

The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. As an investor, you want to buy stocks with the highest probability of success.

shares outstanding

Is holding 865,157 shares at $129,873 based on the most recent closing price. After a stumble in the market that brought ZNTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.13% of loss for the given period. Advisory accounts and services are provided by Webull Advisors LLC (also known as “Webull Advisors”). Webull Advisors is an Investment Advisor registered with and regulated by the SEC under the Investment Advisors Act of 1940. Trades in your Webull Advisors account are executed by Webull Financial LLC, a member of the Securities Investor Protection Corporation .

Eight equities research how to figure out how much to sell for based on profit margin have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $43.44. 8 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Zentalis Pharmaceuticals in the last twelve months. The consensus among Wall Street analysts is that investors should “buy” ZNTL shares. Hedge funds and other institutional investors have recently added to or reduced their stakes in the business.

Barclays PLC increased its stake in Zentalis Pharmaceuticals by 3,284.6% in the 3rd quarter. Barclays PLC now owns 116,598 shares of the company’s stock valued at $2,526,000 after buying an additional 113,153 shares during the last quarter. Sofinnova Investments Inc. increased its stake in shares of Zentalis Pharmaceuticals by 77.6% during the 3rd quarter. Sofinnova Investments Inc. now owns 583,357 shares of the company’s stock worth $12,636,000 after purchasing an additional 254,960 shares during the last quarter.


The book value of a stock is theoretically the amount of money that would be paid to shareholders if the company was liquidated and paid off all of its liabilities. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index quotes are real-time. To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research. We’d like to share more about how we work and what drives our day-to-day business. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams.